PRESS RELEASE March 21 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it s ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the next stage . “After successful completion of target

PRESS RELEASE March 1 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that it will present at multiple upcoming investor conferences. Details are as follows: Redeye Investor Forum – Göteborg, Sweden Date/Time: 10 March 2022, 1:00

PRESS RELEASE February 24 , 202 2 Three Months Ended December 31, 2021 (2020) Revenue was SEK 2.9 M (1.6 M) Operating loss was SEK -125.7 M (-68.6 M) Net loss was SEK -129.9 M (-44.4 M) Basic loss per share was SEK -2.08 (-0.71) Diluted loss per share was SEK -2.08 (-0.71) Twelve Months Ended

PRESS RELEASE February 10 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today provided an update on progress in its Phase 1 clinical trial of SAN711 . The company reported that it has now also initiated the multiple ascending dose stage of the

PRESS RELEASE January 5 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that it will present at multiple upcoming virtual investor conferences. Details are as follows: LifeSci Partners 11th Annual Corporate Access Event (Panel